4.5 Article

The United Kingdom Primary Immune Deficiency (UKPID) registry 2012 to 2017

Journal

CLINICAL AND EXPERIMENTAL IMMUNOLOGY
Volume 192, Issue 3, Pages 284-291

Publisher

WILEY
DOI: 10.1111/cei.13125

Keywords

autoimmunity; autoinflammatory disease; human; immunodeficiency diseases; transplantation

Categories

Funding

  1. Biotest
  2. CSL Behring
  3. Shire (Baxalta)
  4. Shire Israel
  5. Biotest UK
  6. LFB
  7. Shire
  8. Grifols
  9. BPL
  10. Octapharma
  11. UCB Pharma
  12. Binding Site
  13. Sanofi
  14. GSK
  15. SOBI
  16. Baxter
  17. Biotest Immunology Forum - Baxter
  18. BioCryst pharmaceuticals
  19. Novartis pharmaceuticals
  20. Bristol Myers
  21. Octopharma

Ask authors/readers for more resources

This is the second report of the United Kingdom Primary Immunodeficiency (UKPID) registry. The registry will be a decade old in 2018 and, as of August 2017, had recruited 4758 patients encompassing 97% of immunology centres within the United Kingdom. This represents a doubling of recruitment into the registry since we reported on 2229 patients included in our first report of 2013. Minimum PID prevalence in the United Kingdom is currently 590/100000 and an average incidence of PID between 1980 and 2000 of 76 cases per 100000 UK live births. Data are presented on the frequency of diseases recorded, disease prevalence, diagnostic delay and treatment modality, including haematopoietic stem cell transplantation (HSCT) and gene therapy. The registry provides valuable information to clinicians, researchers, service commissioners and industry alike on PID within the United Kingdom, which may not otherwise be available without the existence of a well-established registry.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available